| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10933090 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US10925897 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US11013761 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US10695367 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US11013762 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US10925896 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US10682376 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
|
US10925896 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
|
US10933090 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
|
US10695367 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
|
US11013761 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
|
US11013762 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
|
US10925897 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
|
US10682376 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
| US9561251 | VIFOR FRESENIUS | Pharmaceutical compositions |
Jan, 2030
(6 years from now) | |
|
US9561251 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| US11446252 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(11 years from now) | |
| US11234938 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(11 years from now) | |
| US10624855 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(11 years from now) | |
|
US10624855 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(11 years from now) | |
|
US11446252 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(11 years from now) | |
|
US11234938 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(11 years from now) | |
Velphoro is owned by Vifor Fresenius.
Velphoro contains Ferric Oxyhydroxide.
Velphoro has a total of 22 drug patents out of which 0 drug patents have expired.
Velphoro was authorised for market use on 27 November, 2013.
Velphoro is available in tablet, chewable;oral dosage forms.
Velphoro can be used as control of phosphorous levels in patients.
The generics of Velphoro are possible to be released after 26 May, 2035.
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 27 November, 2013
Treatment: Control of phosphorous levels in patients
Dosage: TABLET, CHEWABLE;ORAL
VELPHORO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic